Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Stomach Neoplasms Clinical Trial

— FOLFIRINOX  

Official title:

Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01928290
• Other study ID #: 201309035
• Status: Completed
• Phase: Phase 2
• Start date: November 8, 2013
• Est. completion date: October 28, 2019

Study information

• Verified date: August 2020
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: October 28, 2019
• Est. primary completion date: December 3, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy-proven and inoperable locally advanced, recurrent, or metastatic cancer of the esophagus, stomach, or gastro-esophageal junction.

2. Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as =10 mm with CT scan, as =20 mm by chest x-ray, or =10 mm with calipers by clinical exam.

3. Prior single modality radiation therapy is allowed.

4. At least 18 years of age.

5. ECOG performance status = 2

6. Normal bone marrow and organ function as defined below:

1. Absolute neutrophil count = 1,500/mcl

2. Platelets = 100,000/mcl

3. AST(SGOT)/ALT(SGPT) = 2.5 x IULN

4. Creatinine = IULN OR creatinine clearance = 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal

5. LVEF = 50%

7. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

8. Ability to understand and willingness to sign an IRB approved written informed consent document (legally authorized representative is allowed).

9. Patients already receiving treatment with FOLFIRINOX +/- trastuzumab may participate in the study and have their data collected retrospectively if they met inclusion criteria at the start of therapy and sign consent for study participation moving forward.

Exclusion Criteria:

1. Chemotherapy in the 6 months prior to registration.

2. Any active malignancy within 3 years that may alter the course of esophageal cancer (Apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed)

3. Receiving any other investigational agents at the time of registration.

4. Known untreated brain metastases. These patients must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.

5. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study.

6. Previous therapy for metastatic gastroesophageal cancer. Previous perioperative chemotherapy is allowed as long as the duration without treatment has been greater than 6 months..

7. A history of congestive heart failure, transmural myocardial infarction, symptomatic valvular disease, or high-risk arrhythmia.

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

9. Pregnant and/or breastfeeding. Patient must have a negative urine pregnancy test within 14 days of study entry.

10. Known HIV-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with trastuzumab. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Inclusion of Women and Minorities

Both men and women and members of all races and ethnic groups are eligible for this trial.

Related Conditions & MeSH terms

• Esophageal Neoplasms
• Neoplasms
• Stomach Neoplasms

Intervention

Drug:
• Irinotecan

• Trastuzumab

• Oxaliplatin

• Leucovorin

• Fluorouracil

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With an Objective Response	Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria); CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.	Through completion of treatment (estimated to be 4 months)
Secondary	Progression Free Survival	Duration of time from start of treatment to time of progression or death, whichever occurs first.	Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Secondary	Time to Progression (TTP)	Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.	Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Secondary	Overall Survival (OS)	Overall survival is defined as the time interval from date of diagnosis to date of death from any cause.	Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Secondary	Clinical Benefit Rate	Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD); CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm; PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.	Through completion of treatment (estimated to be 4 months)
Secondary	Duration of Response	Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented	Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
Secondary	Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events		30 days after completion of treatment (estimated to be 5 months)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine